Patent application number | Description | Published |
20110053880 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS - The invention relates to a pharmaceutical composition comprising a compound preventing EthR from binding to the ethA promoter, for example a compound of formula 1 wherein R | 03-03-2011 |
20110151006 | STIMULI-RESPONSIVE HYDROGEL - The present invention relates to a hydrogel comprising a polymer, a first polypeptide and a polypeptide binding partner, wherein the polypeptide binding partner is a second polypeptide, a nucleic acid or a small molecule, and wherein the interaction between the first polypeptide and the polypeptide binding partner stabilizes the hydrogel and is modulated by the addition of a modulating compound. A drug may be physically entrapped in the hydrogel, bound to the polymer forming the hydrogel structure, or bound to the first polypeptide or the polypeptide binding partner, and then be set free on addition of the modulating compound. Such a hydrogel comprising a drug may be injected into a patient, and drug release modulated by orally administering the modulating compound. | 06-23-2011 |
20110177162 | DEGRADABLE MICROCAPSULES - The invention relates to microcapsules consisting of a polymer degradable by a polypeptide comprising a drug or other compound of interest and a genetically engineered cell expressing said polypeptide in response to a triggering compound, and to methods of directed release of the compound of interest. The preferred polymer is optionally modified cellulose sulfate/poly-diallyl-dimethyl-ammonium chloride. Such microcapsules are non-toxic, do not elicit an immunological response and have an extended half-life time in mammals. The expression system for cellulase is, for example, based on TET and doxycycline, or E.REX and erythromycin. In another example, expression of cellulase is triggered by luteinizing hormone, which can be used for artificial insemination with microcapsules carrying sperm. | 07-21-2011 |
20120029074 | CONTROLLING TRANSGENE EXPRESSION ACROSS THE SKIN - The invention relates to the use of a skin permeating compound such as phloretin for controlling transgene expression under control of the | 02-02-2012 |
20120066778 | CONTROL OF URIC ACID HOMEOSTASIS - The invention relates to vectors and mammalian cells in a system useful for switching on or switching off gene expression in response to uric acid. In a particular embodiment the invention relates to a mammalian cell useful in detecting and/or degrading a harmful excess of uric acid comprising (a) a vector comprising a genetic code for the uricase sensor-regulator HucR from | 03-15-2012 |
20120101080 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS - The invention relates to a pharmaceutical composition comprising a compound of formula (1) wherein R | 04-26-2012 |
20130045190 | DEGRADABLE MICROCAPSULES - The invention relates to microcapsules consisting of a polymer degradable by a polypeptide comprising a drug or other compound of interest and a genetically engineered cell expressing said polypeptide in response to a triggering compound, and to methods of directed release of the compound of interest. The preferred polymer is optionally modified cellulose sulfate/poly-diallyl-dimethyl-ammonium chloride. Such microcapsules are non-toxic, do not elicit an immunological response and have an extended half-life time in mammals. The expression system for cellulase is, for example, based on TET and doxycycline, or E.REX and erythromycin. In another example, expression of cellulase is triggered by luteinizing hormone, which can be used for artificial insemination with microcapsules carrying sperm. | 02-21-2013 |
20140059709 | CONTROL OF URIC ACID HOMEOSTASIS - The invention relates to vectors and mammalian cells in a system useful for switching on or switching off gene expression in response to uric acid. In a particular embodiment the invention relates to a mammalian cell useful in detecting and/or degrading a harmful excess of uric acid comprising (a) a vector comprising a genetic code for the uricase sensor-regulator HucR from | 02-27-2014 |